These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Jeon HJ, Choi JH, Jung IH, Park JG, Lee MR, Lee MN, Kim B, Yoo JY, Jeong SJ, Kim DY, Park JE, Park HY, Kwack K, Choi BK, Kwon BS, Oh GT. Circulation; 2010 Mar 09; 121(9):1124-33. PubMed ID: 20176988 [Abstract] [Full Text] [Related]
6. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Olofsson PS, Söderström LA, Wågsäter D, Sheikine Y, Ocaya P, Lang F, Rabu C, Chen L, Rudling M, Aukrust P, Hedin U, Paulsson-Berne G, Sirsjö A, Hansson GK. Circulation; 2008 Mar 11; 117(10):1292-301. PubMed ID: 18285570 [Abstract] [Full Text] [Related]
8. Histamine H1 receptor promotes atherosclerotic lesion formation by increasing vascular permeability for low-density lipoproteins. Rozenberg I, Sluka SH, Rohrer L, Hofmann J, Becher B, Akhmedov A, Soliz J, Mocharla P, Borén J, Johansen P, Steffel J, Watanabe T, Lüscher TF, Tanner FC. Arterioscler Thromb Vasc Biol; 2010 May 11; 30(5):923-30. PubMed ID: 20203300 [Abstract] [Full Text] [Related]
9. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Bousette N, D'Orleans-Juste P, Kiss RS, You Z, Genest J, Al-Ramli W, Qureshi ST, Gramolini A, Behm D, Ohlstein EH, Harrison SM, Douglas SA, Giaid A. Circ Res; 2009 Sep 25; 105(7):686-95, 19 p following 695. PubMed ID: 19696412 [Abstract] [Full Text] [Related]
18. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Zhou X, Stemme S, Hansson GK. Am J Pathol; 1996 Aug 25; 149(2):359-66. PubMed ID: 8701976 [Abstract] [Full Text] [Related]
19. Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development. Guo J, de Waard V, Van Eck M, Hildebrand RB, van Wanrooij EJ, Kuiper J, Maeda N, Benson GM, Groot PH, Van Berkel TJ. Arterioscler Thromb Vasc Biol; 2005 May 25; 25(5):1014-9. PubMed ID: 15774908 [Abstract] [Full Text] [Related]
20. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Böckler D, Katus HA, Dengler TJ. J Immunol; 2009 Dec 15; 183(12):8167-75. PubMed ID: 20007582 [Abstract] [Full Text] [Related] Page: [Next] [New Search]